Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
31.1M
-
Shares change
-
-232K
-
Total reported value, excl. options
-
$444M
-
Value change
-
-$29M
-
Put/Call ratio
-
1.23
-
Number of buys
-
89
-
Number of sells
-
-76
-
Price
-
$14.27
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q2 2021
218 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2021.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.1M shares
of 54.8M outstanding shares and own 56.78% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.3M shares), VANGUARD GROUP INC (2.75M shares), Farallon Capital Management LLC (2M shares), STATE STREET CORP (1.62M shares), RHO CAPITAL PARTNERS INC (1.5M shares), Chescapmanager LLC (1.3M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.05M shares), GEODE CAPITAL MANAGEMENT, LLC (792K shares), Assenagon Asset Management S.A. (732K shares), and DISCIPLINED GROWTH INVESTORS INC /MN (675K shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.